<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871893</url>
  </required_header>
  <id_info>
    <org_study_id>CRRT-CVVHD/HDF-01-D</org_study_id>
    <nct_id>NCT04871893</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy</brief_title>
  <acronym>multiECCO2R</acronym>
  <official_title>Safety and Effcacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy (A Clinical Study in Patients With Combined Renal Failure and Hypercapnia Due to Acute Lung Failure in COVID-19 and Other Forms of Respiratory Insufficiency)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CERES GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of the study is to assess the safety and efficacy of CO2 removal by the multiECCO2R&#xD;
      (CO2 Removal System) on the multiFiltrate/multiFiltrate Pro in veno-venous extracorporeal&#xD;
      circulation during continuous renal replacement therapy (CRRT) in patients presenting with&#xD;
      hypercapnia due to acute lung failure and acute kidney injury.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 11, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-comparative, multi-centre, open-label, interventional PMCF study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical efficiency variables: Change of PaCO2</measure>
    <time_frame>30 minutes after start of treatment</time_frame>
    <description>Reduction of PaCO2 during the first 30 minutes of treatment (Blood-gas analysis (BGA))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical efficiency variables: Change of pCO2</measure>
    <time_frame>72 hours after start of treatment</time_frame>
    <description>Reduction of pCO2 within the extracorporeal circuit by pre- and post- CO2-exchanger during the treatment (Blood-gas analysis (BGA))</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lung Injury</condition>
  <condition>Acute Kidney Injury</condition>
  <condition>Hypercapnia</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Treatment with the blood-gas exchanger multiECCO2R for CO2 removal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>multiECCO2R blood-gas exchanger</intervention_name>
    <description>Treatment with the blood-gas exchanger multiECCO2R for CO2 removal</description>
    <arm_group_label>Treatment with the blood-gas exchanger multiECCO2R for CO2 removal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent signed and dated by the investigator; and:&#xD;
&#xD;
               1. if patient is able to give consent: by the study patient&#xD;
&#xD;
               2. if patient is unable to give consent: by the legal representative or&#xD;
&#xD;
               3. if an emergency situation is determined: by an independent consultant physician&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
        Study-specific:&#xD;
&#xD;
          -  Body weight greater than 40 kg&#xD;
&#xD;
          -  Acute Kidney Injury (AKI) with clinical indication for CRRT&#xD;
&#xD;
          -  Hypercapnia with indication for ECCO2R:&#xD;
&#xD;
        (paCO2 ≥ 55 mmHg at given ventilation parameters: tidal volume = 6 ml/kg PBW, PEEP to be&#xD;
        adjusted according to the FiO2 , driving pressure &lt; 15 cmH2O, max. inspiratory pressure &lt;&#xD;
        30 cmH2O or TV=5 mmHg when max. inspiratory pressure&lt; 30 cmH2O cannot be held)&#xD;
&#xD;
          -  Vascular access and Shaldon catheter allowing blood flow of 100 ml/min to 500 ml/min&#xD;
&#xD;
          -  Arterial line in place, allowing blood sampling&#xD;
&#xD;
          -  Estimated life expectancy greater than 3 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years&#xD;
             old or have been surgically sterilized, a negative pregnancy test is not required)&#xD;
&#xD;
          -  Participation in an interventional clinical study during the preceding 72 hours&#xD;
&#xD;
          -  Previous participation in the same study&#xD;
&#xD;
        Study-specific&#xD;
&#xD;
          -  Severe ARDS (Berlin definition): PaO2/FiO2 &lt; 100 mmHg&#xD;
&#xD;
          -  Intracerebral haemorrhage&#xD;
&#xD;
          -  Intracranial hypertension&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Acute myocardial infarction&#xD;
&#xD;
          -  Hypersensitivity to heparin or known history of heparin induced thrombocytopenia (HIT&#xD;
             Type II), if heparin is used as anticoagulant&#xD;
&#xD;
          -  severe liver insufficiency or fulminant hepatic failure&#xD;
&#xD;
          -  Uncontrolled bleeding and coagulation disorders, thrombocytopenia &lt; 75000/nL&#xD;
&#xD;
          -  Liver cirrhosis CHILD Pugh Classification &gt; A&#xD;
&#xD;
          -  BMI &gt; 40 kg/m²&#xD;
&#xD;
          -  Decision to limit therapeutic interventions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Müller, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Lubnow, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Stauss-Grabo, Dr.</last_name>
    <phone>+49 6172 608 5248</phone>
    <email>Manuela.Stauss-Grabo@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Wammi</last_name>
    <phone>+49 6172 609 7634</phone>
    <email>anna.wammi@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Medizin</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas Müller, Prof. Dr.</last_name>
      <phone>+49 941 944 17356</phone>
      <email>thomas.mueller@ukr.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CO2 removal</keyword>
  <keyword>Continuous Renal Replacement Therapy</keyword>
  <keyword>blood-gas exchanger</keyword>
  <keyword>CRRT</keyword>
  <keyword>multiECCO2R</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

